The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening

Affiliations

• ¹ UMIT - University for Health Sciences, Medical Informatics and Technology / Oncotyrol - Center for Personalized Cancer Medicine, Hall i. T. / Innsbruck, Austria.
• ² Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands.
• ³ Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada.
• ⁴ University Health Network, Toronto, ON, Canada.
• ⁵ Cancer Registry of Tyrol, TILAK GmbH, Innsbruck, Austria.
• ⁶ Department of Urology, Innsbruck Medical University, Innsbruck, Austria.
• ⁷ UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria.
• ⁸ UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL - Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria.
• ⁹ Medical Informatics and Technology, and Director of the Division for Health Technology Assessment and Bioinformatics, ONCOTYROL, Hall i. T, Austria.